CyFlow™ HLA-E Purified

| Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA‑G or HLA‑E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 Mar; 64(3):315‑26. < PMID: 12590976 > | Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP: HLA‑E surface expression is independent of the availability of HLA class I signal sequence‑derived peptides in human tumor cell lines. Hum Immunol. 2005 Jan; 66(1):42705. < PMID: 15620456 > | Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsí V, Goldman-Wohl D, Yagel S, Mandelboim O: The CD85J/leukocyte inhibitory receptor‑1 distinguishes between conformed and beta 2‑microglobulin‑free HLA‑G molecules. J Immunol. 2005 Oct 15; 175(8):4866‑74. < PMID: 16210588 > | Dambaeva SV, Bondarenko GI, Grendell RL, Kravitz RH, Durning M, Golos TG: Non‑classical MHC‑E (Mamu‑E) expression in the rhesus monkey placenta. Placenta. 2008 Jan; 29(1):58‑70. < PMID: 17996936 > | Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. 2011 Sep; 13(9):822‑30. < PMID: 21969815 >